Results - Announcements
Tatva Chintan Pharma Chem Ltd share price softened by 2.08% to Rs 1900.05. The Company's net profit soared by 34.23% to Rs 21.45 crore, while revenue from operations gained significantly 30.08% to Rs 217.32 crore in Q3FY26 over Q2FY26.
The market capitalization of Specialty Chemicals industry group stocks on BSE stood at Rs 5.46 lakh crore, rallying 15.84%. It has slipped by 3.31% over last one week and eased lower by 0.36% in last one month while the market capitalization of Tatva Chintan Pharma Chem Ltd has eased by 2.27% and 11.69% in the same period respectively.
Profit before tax (PBT) of Tatva Chintan Pharma Chem Ltd stood at Rs 28.94 crore in Q3 FY26, expanding by 111.86% year-on-year, and surging by 37.09% quarter-on-quarter. EBITDA came in at Rs 39 crore, jumping 83.68% YoY and surging by 31.91% sequentially.
Total expenses witnessed a sharp rise of 28.97% to Rs 187.43 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 114.05 crore, inching up 8.20% YoY, while employee benefits expense was at Rs 18.23 crore, rising by 8.90% YoY.
For the TTM ended FY26, revenue from operations witnessed a strong growth of 32.18% to Rs 505.86 crore, while net profit jumped 636.43% to Rs 42.05 crore, compared to previous TTM. EBITDA surged by 4008% to Rs 89.61 crore, and PBT soared 652.11% to Rs 57.01 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 31.49 crore in FY26, as against Rs 24.67 crore in FY25.
Tatva Chintan Pharma Chem Ltd surged by 37.83% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 12.46% during the same period.